Ischemic stroke and antithrombotic therapy: key aspects
https://doi.org/10.21518/2079-701X-2019-18-10-17
Abstract
The paper considers the key areas of antithrombotic therapy for ischemic stroke (IS). Antiplatelet therapy is shown to be a multistage and multidisciplinary strategy of treatment for patients with IS, which begins with the appearance of the first symptoms of the disease and continues throughout life. Each stage, including fibrinolytic therapy, early use of antithrombotic and anticoagulant drugs, and personalized antithrombotic prevention of recurrent cerebral disorders, is important in itself and serves a common goal. As a result, all efforts should be aimed at reducing mortality rates in the acute phase of stroke and the functional dependence of a patient and at preventing venous thromboses, recurrent stroke, and all cardiovascular events to increase life expectancy and to improve quality of life. Fibrinolytic therapy increases the patient’s chances of a full neurologic recovery and improves the quality of later life. Antithrombotic drugs reduce the risk of cardiovascular death, early recurrences of stroke, and recurrent noncardioembolic stroke. Parenteral anticoagulants in acute stroke decrease the risk of venous thrombosis/thromboembolism, oral anticoagulants reduce that of recurrent cardioembolic stroke.
About the Authors
M. Yu. Maksimova
Federal State Budgetary Scientific Institution «Research Center of Neurology»
Russian Federation
Russian Federation
Marina Yu. Maksimova, Dr. of Sci. (Med), professor, Head of the 2nd Neurological Department
80, Volokolamskoe shosse, Moscow, 125367
A. V. Fonyakin
Federal State Budgetary Scientific Institution «Research Center of Neurology»
Russian Federation
Russian Federation
Andrey V. Fonyakin, Dr. of Sci. (Med), professor, Head of the Cardio-Neurology Laboratory of the 2nd Neurological Department, leading researcher
80, Volokolamskoe shosse, Moscow, 125367
L. A. Geraskina
Federal State Budgetary Scientific Institution «Research Center of Neurology»
Russian Federation
Russian Federation
Lyudmila A. Geraskina, Dr. of Sci. (Med), professor, Leading Researcher of the Cardio-Neurology Laboratory of the 2nd Neurological Department
80, Volokolamskoe shosse, Moscow, 125367
References
1. Piradov M.A., Tanashyan M.M., Maksimova M.Yu. (eds.). Insult: modern technology of diagnostic and treatment. Moscow: MEDPress-Inform; 2018. 360 с. (In Russ.) doi: 10.24421/МР.2018.18.15909.
2. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attacks 2008. Cerebrovasc Dis. 2008;25:457507. doi: 10.1159/000131083.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:15811587. doi: 10.1056/NEJM199512143332401.
4. Powers W.J., Rabinstein A.A., Ackerson T. et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e99. doi: 10.1161/STR.0000000000000158.
5. IST-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12(8):768-776. doi: 10.1016/S1474-4422(13)70130-3.
6. Hacke W., Kaste M., Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: http://dx.doi. org/10.1056/NEJMoa0804656.
7. Del Zoppo G.J., Saver J.L., Jauch E.C., Adams H.P. Jr.; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):29452948. doi: 10.1161/STROKEAHA.109.192535.
8. Lees K., Bluhmki E., von Kummer R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–1703. doi:: 10.1016/S0140-6736(10)60491-6.
9. Piradov M.A., Domashenko M.A., Maksimova M.YU. Reperfusion methods of ischemic stroke treatment. In the book: Piradov M.A., Illarioshkin S.N., Tanashyan M.M. (ed.). Neurology in the 21st Century: diagnostic, therapeutic and research technologies: a guide for physicians. VOL. II. Hightechnology methods of treatment and rehabilitation in neurology. In 3 vol. Moscow: ATMO; 2015:9-45. (In Russ.)
10. Skvortsova V.I., Shetova I.M., Kakorina E.P., Kamkin E.G., Boyko E.L., Dashyan V.G., Krylov V.V. Healthcare system for patients with stroke in Russia. Results of 10-years implementation of the measures aimed at improvement of medical care for patients with acute cerebrovascular events. Annals of clinical and experimental neurology. 2018;12(3):5–12. (In Russ.). doi: 10.25692/ACEN.2018.3.1.
11. Shamalov N.A. Reperfusion therapy for ischemic stroke in Russian Federation: problems and perspectives. Nevrologiya, neiropsikhiatriya, psihosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;(Special Issue 2):15-21. (In Russ.) doi: 10.14412/20742711-2014-2S-15-21.
12. Bhatia R., Hill M.D., Shobha N. et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254-2258. doi: 10.1161/STROKEAHA.110.592535.
13. Broderick J.P., Palesch Y.Y., Demchuk A.M. et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903. doi: 10.1056/ NEJMoa1214300.
14. Riedel C.H., Zimmermann P., Jensen-Kondering U. et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011;42(6):1775-1777. doi: 10.1161/STROKEAHA.110.609693.
15. Wardlaw J.M., Zoppo G., Yamaguchi T., Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858. CD000213.
16. Lansberg M.G., Thijs V.N., Bammer R. et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke. 2007;38:2275– 2278. doi: 10.1161/STROKEAHA.106.480475.
17. Whiteley W.N., Slot K.B., Fernandes P. et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies Stroke. 2012;43(11):2904-9. doi: 10.1161/STROKEAHA.112.665331.
18. Domashenko M.A., Maksimova M.Yu., Gafarovа M.E. et al. Personification of the approaches to reperfusion therapy of ischeamic stroke. Annaly Klinicheskoy I Experimental’noy Nevrologii = Annals of Clinical and Experimental Neurology. 2017;11(1):7–13. (In Russ.) Available at: http://www.annaly-nevrologii.ru/ journals/44-tom-11-1-2017.pdf.
19. Alexandrov A.V., Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002; 59(6):862-867. doi: 10.1212/wnl.59.6.862.
20. Rubiera M., Alvarez-Sabín J., Ribo M. et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36(7):1452-1456. doi: 10.1161/01. STR.0000170711.43405.81.
21. Breuer L., Blinzler C., Huttner H.B. et al. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc Dis. 2011;32(2):177-185. doi: 10.1159/000328811.
22. Guillan M., Alonso-Canovas A., Garcia-Caldentey J. et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 2012;19(3):390-394. doi: 10.1111/j.1468-1331.2011.03517.
23. Domashenko M.A., Maksimova M.Yu., Kistenev B.A., Loskutnikov М.А., et al. Intravenous thrombolysis in acute ischemic stroke. Annaly Klinicheskoy I Experimental’noy Nevrologii = Annals of Clinical and Experimental Neurology. 2008;2(2):5-12. (In Russ.) Available at: https:// elibrary.ru/item.asp?id=15130945.
24. Powers W.J., Derdeyn C.P., Jauch E.C. et al. on behalf of the American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:3024-3039. doi: 10.1161/ STR.0000000000000074.
25. Binning M.J., Bartolini B., Baxter B. et al. Trevo 2000: Results of a Large Real-World Registry for Stent Retriever for Acute Ischemic Stroke. J Am Heart Assoc. 2018;7:e010867. doi: 10.1161/JAHA.118.010867.
26. CAST (Chinese Acute Stroke Trial) Collabora tive Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349(9066):1641-1649. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9186381.
27. IST (International Stroke Trial) Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349(9065):1569-1581. Available at: https:// www.ncbi.nlm.nih.gov/pubmed/9174558.
28. Chen Z.M., Sandercock P., Pan H.C. et al. Indi ca tion for early aspirin use in acute ischemic stro ke. A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000;31(6):12401249. doi: 10.1161/01.str.31.6.1240.
29. Wang Y., Wang Y., Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19. doi: 10.1056/NEJMoa1215340.
30. Zuo F.-T., Liu H., Wu H.-J. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese Patients A randomized and controlled trail. Medicine (Baltimore). 2017;96(1):1-6. doi: 10.1097/MD.0000000000005497 .
31. Antithrombotic Trialists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.
32. He J., Whelton P., Vu B., Klag M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280(22):19301935. doi: 10.1001/jama.280.22.1930.
33. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339. doi: 10.1016/s0140-6736(96)09457-3.
34. Diener H.C., Bogousslavsky J. Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331337. doi: 10.1016/S0140-6736(04)16721-4.
35. Bhatt D.L., Fox K.A.A., Hacke W. et al. CHARISMA investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717 . doi: 10.1056/NEJMoa060989.
36. SPS3 Investigators; Benavente O.R., Hart R.G., McClure L.A. et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825. doi: 10.1056/NEJMoa1204133.
37. The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:16651673. doi: 10.1016/S0140-6736(06)68734-5.
38. Diener H.C., Sacco R.L., Yusuf S., Steering Committee of PROFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis. 2007;23(56):368–380. doi: 10.1159/000100105.
39. Costa J., Ferro J.M., Matias-Guiu J. et al. Trifluzal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005;(3):CD004296. doi: 10.1002/14651858.CD004296.pub2.
40. Huang Y., Cheng Y., Wu J. et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008;7:494-499. doi: 10.1016/S14744422(08)70094-2.
41. Shinohara Y., Katayama Y., Uchiyama S. et al.; CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–968. doi: 10.1016/S1474-4422(10)70198-8.
42. Shinohara Y., Nishimaru K., Sawada T. et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke. 2008;39:1827-1833. doi: 10.1161/ STROKEAHA.107.505131.
43. Johnston S.C., Amarenco P., Albers G.W. et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016;375:35-43. doi: 10.1056/NEJMoa1603060.
44. Amarenco P., Albers G.W., Denison H. et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301310. doi: 10.1016/S1474-4422(17)30038-8.
45. Suslina Z.A., Fonyakin A.V., Kusnetsov A.L. Cardioembolic stroke: embolic sauces and prophylaxis. Atmosfera. Novosti kardiologii = Atmosphere. News of cardiology. 2004;(2):13-16. (In Russ.) Available at: https://elibrary.ru/item. asp?id=24120158.
46. Kernan W.N., Ovbiagele B., Black H.R. et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1007/s11940-014-0315-4.
47. Fonyakin A.V., Geraskina L.A. Prophylactics of ischemic stroke. Antithrombotic recomendations. Suslina Z.A. (ed.). Moscow: IMA-Press; 2014. 72 p. (In Russ.)
48. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210.
49. Steffel J., Verhamme P., Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation European Heart Journal. 2018;39:1330-1393. doi: 10.1093/eurheartj/ehy136.
50. Paciaroni M., Agnelli G., Micheli S., Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–430. doi: 10.1161/01. STR.0000254600.92975.1f.
Review
For citations:
Maksimova MY, Fonyakin AV, Geraskina LA. Ischemic stroke and antithrombotic therapy: key aspects. Meditsinskiy sovet = Medical Council. 2019;(18):10-17. (In Russ.) https://doi.org/10.21518/2079-701X-2019-18-10-17
Views:
1316
Email this article 